Pharmaceutical Partners

Janssen Biotech (Johnson & Johnson)

This collaboration was signed in December 2011 to develop multiple Phylomer-based drug candidates using novel cell-penetrating peptides derived from Phylogica's Phylomer® platform. Janssen has the option to expand the scope of the collaboration for the development of a further ten drug candidates. Phylogica received an upfront payment; is eligible to receive research funding over a minimum of 18 months; and could receive further research funding, license fees, milestone payments and royalties on worldwide sales.

Press release 2012 (pdf, 111 kB)

Pfizer

This collaboration was signed in December 2010 to discover novel peptide vaccines derived from Phylogica's Phylomer® platform. Phylogica received an upfront payment of US$0.5 million and is eligible to receive further payments of up to US$134 million as well as royalties on worldwide sales. In December 2011, Phylogica received an undisclosed milestone payment for successfully completing the first stage of the collaboration.

Phylogica and Pfizer Complete First Stage Of Peptide Vaccine Collaboration (pdf, 124 kB)
Press release 2010 (pdf, 87 kB)

MedImmune (AstraZeneca)

This collaboration was signed in August 2010 to discover novel antibiotic peptides derived from Phylogica's Phylomer® platform for the treatment of hospital acquired infection. Phylogica has received payments of US$1.5 million and is eligible to receive further payments of up to US$98 million plus royalties on worldwide sales.

Press release 2011 (pdf, 112 kB)
Press release 2010 (pdf, 87 kB)

Roche

This collaboration was signed in December 2009 and extended in May 2011. The collaboration relates to cell-penetrating peptides derived from Phylogica's Phylomer® platform for delivery across the blood-brain barrier. Terms and conditions of the collaboration were undisclosed.

Press release 2010 (pdf, 79 kB)
Press release 2011 (pdf, 34 kB)